Brokers Set Expectations for Amarin Co. plc’s Q2 2025 Earnings (NASDAQ:AMRN)

Amarin Co. plc (NASDAQ:AMRN) – Investment analysts at Zacks Research cut their Q2 2025 earnings per share estimates for shares of Amarin in a research note issued on Tuesday, April 30th. Zacks Research analyst R. Department now anticipates that the biopharmaceutical company will post earnings of ($0.06) per share for the quarter, down from their prior estimate of ($0.05). The consensus estimate for Amarin’s current full-year earnings is ($0.14) per share. Zacks Research also issued estimates for Amarin’s Q1 2026 earnings at ($0.05) EPS.

Amarin (NASDAQ:AMRN) last announced its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.02. Amarin had a negative net margin of 18.96% and a negative return on equity of 9.48%. The firm had revenue of $56.52 million for the quarter, compared to analysts’ expectations of $51.34 million. During the same period in the previous year, the company posted ($0.04) earnings per share.

Separately, Cantor Fitzgerald reissued an “overweight” rating on shares of Amarin in a research report on Friday, January 12th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $1.08.

Amarin Trading Down 0.9 %

Shares of AMRN stock opened at $0.91 on Friday. The company’s fifty day simple moving average is $0.94 and its 200-day simple moving average is $0.94. Amarin has a 52 week low of $0.65 and a 52 week high of $1.49. The company has a market cap of $373.71 million, a PE ratio of -7.58 and a beta of 1.96.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. increased its stake in Amarin by 351.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 44,599 shares of the biopharmaceutical company’s stock worth $39,000 after buying an additional 34,725 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Amarin by 16.8% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 122,498 shares of the biopharmaceutical company’s stock worth $113,000 after acquiring an additional 17,613 shares during the last quarter. SVB Wealth LLC lifted its stake in shares of Amarin by 100.0% in the fourth quarter. SVB Wealth LLC now owns 60,000 shares of the biopharmaceutical company’s stock worth $52,000 after acquiring an additional 30,000 shares in the last quarter. Raymond James Financial Services Advisors Inc. boosted its holdings in Amarin by 35.7% in the third quarter. Raymond James Financial Services Advisors Inc. now owns 649,152 shares of the biopharmaceutical company’s stock valued at $597,000 after purchasing an additional 170,670 shares during the last quarter. Finally, Tokio Marine Asset Management Co. Ltd. boosted its holdings in Amarin by 18.9% in the third quarter. Tokio Marine Asset Management Co. Ltd. now owns 129,200 shares of the biopharmaceutical company’s stock valued at $119,000 after purchasing an additional 20,500 shares during the last quarter. 22.25% of the stock is owned by institutional investors and hedge funds.

Amarin Company Profile

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.